Navigation Links
Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer

peutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus (RSV) infection. RSV infects nearly every child at least once by the age of two and accounts for more than 100,000 hospitalizations annually in the U.S. pediatric population. RSV infection also poses a great risk to the elderly and other adults with compromised immune systems. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec. The company, founded in 2002, maintains global headquarters in Cambridge, Massachusetts, and has an additional operating unit in Kulmbach, Germany. For more information, visit www.alnylam.com.

Alnylam Forward-Looking Statements

Various statements in this release concerning our future expectations, plans, and prospects, including statements concerning the timing of filing an IND for ALN-VSP01, statements concerning use of RNAi therapeutics for the treatment of liver and other cancers, statements concerning use of siRNAs to achieve therapeutic silencing of genes and statements concerning effective delivery of siRNAs, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our approach to discover and develop novel drugs, which is unproven and may never lead to marketable products; our ability to fund and the results
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Alnylam Reports Results of Human Experimental Infection Model with Respiratory Syncytial Virus
2. Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
(Date:12/17/2014)... STUTTGART , Alemania, December 17, 2014 ... del año anterior, con un alto nivel de gasto ... pasado año fiscal 2013/14 (finalizado el 30 de septiembre ... por ciento a 4.287 millones de euros (año anterior: ... de la moneda desfavorables. Las ganancias (EBIT) crecieron un ...
(Date:12/17/2014)... , Dec. 17, 2014  Northstar Global ... Depository Trust Company (DTC) has made their final ... Chill on the Company,s stock effective December 15, ... common stock for depository and book entry transfer ... Company is now once again fully "DTC Eligible", ...
Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3ZEISS confirma su posición en un entorno difícil 2Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3
... 8, 2011 INNOPHARMA LLC announced ... for levetiracetam injection (the generic equivalent of Keppra® injection from ... injectable drug, INNOPHARMA entered into a license agreement with X-GEN ... About INNOPHARMA: INNOPHARMA ...
... 8, 2011 Echo Therapeutics, Inc. (Nasdaq: ... as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) ... delivery, today announced the receipt of notices of issuance ... notices of registration for the trademarks PRELUDE and SYMPHONY. ...
Cached Medicine Technology:Echo Therapeutics Announces Multiple Patents and Trademark Grants 2Echo Therapeutics Announces Multiple Patents and Trademark Grants 3
(Date:12/20/2014)... 20, 2014 Developers of FCPX ... a new plugin for Final Cut Pro X entitled ... Volume 5 allows users to create hand drawn text ... Christina Austin, CEO of Pixel Film Studios. “TranSlice Volume ... while maintaining an easy to use interface.” , TranSlice ...
(Date:12/20/2014)... 20, 2014 Today, Balfleet.com, one of ... Christmas Sale, offering 50%-70% off on its Mother ... , The mother of the bride dresses from Balfleet.com ... is 24/7 accessible and takes pride in providing high ... “We are offering great discounts on our mother of ...
(Date:12/19/2014)... Sub Zero Ice Cream is partnering up ... Sunday the 28th from 2pm-6pm at the Expo Center on ... Sarasota, FL. , Inquiries regarding time slots and signing up, ... the donating process, Sub Zero Ice Cream & Yogurt will ... cream. , About Sub Zero Ice Cream & Yogurt ...
(Date:12/19/2014)... SuperCloset raises the bar once again, with ... offer indoor growers the most efficient and effective indoor ... Rooms with the award winning SuperRooms for ... room setup. , The SuperClone Room features the most ... 50 . The SuperClone Room pairs this ...
(Date:12/19/2014)... The Medspa at Hendrick in Abilene, TX ... cosmetic brand Juvéderm. Voluma XC treats volume loss in ... at Hendrick is pleased to be able to offer ... its clients. , Voluma is the first and only ... the mid-face and cheek area. This non-invasive treatment targets ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2
... , , NEWPORT, Ky., June 4 Xanodyne ... Valentino has been named to the position of President ... of the Company,s Board of Directors. In addition to ... $38 million led by MPM Capital. Current investors, participation ...
... PARK, Calif., June 4 XTENT, Inc. (Nasdaq: ... from the United States Food and Drug Administration (FDA) for ... pivotal clinical program, composed of two pivotal trials called CUSTOM ... the United States of its Custom NX(R) Drug Eluting ...
... California Cryobank , a leader in ... off-site collection center at Reproductive Medicine Associates ... center. The off-site collection center will provide fertility preservation ... , , Known worldwide for outstanding donor semen services, ...
... Ross ... the Center for Haitian Studies (CHS)/Greater Miami Health Education and Training Center (GMHETC). ... North Brunswick, NJ ... will add new clinical rotations in obstetrics and gynecology (OB/GYN) to its growing network ...
... ... Department published results from a promising yearlong study conducted with pediatric ... to keep them taking critical medication on schedule. By sending text ... patients experienced a rejection episode versus 12 patients prior to the ...
... ... and selfless acts of courage that help make the IMD one of Chicago’s safest places ... ... largest urban medical district, recognized its honored District Security Group (DSG) Members and their service ...
Cached Medicine News:Health News:Xanodyne Announces New President/CEO and Completes $38 Million Equity Financing 2Health News:XTENT, Inc. Receives Conditional Approval for Investigational Device Exemption of Custom NX(R) Drug Eluting Stent System from United States Food and Drug Administration 2Health News:XTENT, Inc. Receives Conditional Approval for Investigational Device Exemption of Custom NX(R) Drug Eluting Stent System from United States Food and Drug Administration 3Health News:Leading Sperm Bank Expands Fertility Preservation Services to the Big Apple 2Health News:Ross University School of Medicine Expands Clinical Rotations in Miami 2Health News:Text Messaging Medication Reminders Significantly Reduces Organ Rejection in Pediatric Liver Transplant Recipients 2Health News:Text Messaging Medication Reminders Significantly Reduces Organ Rejection in Pediatric Liver Transplant Recipients 3Health News:Illinois Medical District Recognizes Officers of its District Security Group 2
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
... KWIK-QC Slides have a positive and ... sample inoculation. With these slides, perform QC ... ,Laboratories enhance their education and training programs ... and interpretation, all on one slide! KWIK-QC ...
Each slide contains Giardia lamblia trophozoites applied as a mono-layer to the side....
Each slide contains a high yield of concentrated C. parvum oocysts within the positive control well. A negative control well is also included....
Medicine Products: